Scott & White receives grant for prostate cancer research
- Million dollar grant will fund study of new drug delivery system -
TEMPLE, Texas – The Department of Urology at Scott & White Memorial Hospital in Temple, in collaboration with Twin Star Medical, Inc., and Therataxis, Inc., received a grant for more than $1 million from the National Institutes of Health (NIH) to research an alternative delivery system to treat prostate cancer. The study will investigate the use of a micro hollow fiber catheter (MHFC) to inject medical therapies into the prostate for both benign and malignant diseases.
"The MHFC in this research study will be investigated to plan and deliver therapeutic agents into the prostate,"said Scott Coffield, MD, research director of urology at Scott & White Healthcare and the principal investigator to the study. "The reliable and predictable delivery of these agents will reduce the side effects and cost of treating frequently occurring prostatic diseases."
Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer. The American Cancer Society estimates that in 2013 about 238,590 new cases of prostate cancer will be diagnosed with an average age of 67. Though most of the 2.5 million Americans currently living with the disease will survive, about one in 36 men will die.
"The goal of this research is to further develop an innovative drug delivery system for improved prostate disease therapies, as well as provide the bench and study data required to accelerate its clinical use" said Dr. Coffield. "Also, by switching to the minimally invasive direct injection of therapeutic agents into the prostate, there is a significant reduction of risks, lower cost and, ultimately, improved patient care."
The NIH award is comprised of Twin Star, Therataxis, and Scott & White. Twin Star and Therataxis will provide the method drug delivery devices which are less invasive and/or in a more effective manner than the past. As the age of molecular biology progresses, and the potential for being able to deliver tissue altering therapies in molecular forms continues to advance, those suffering from prostate cancer could benefit from this type of treatment.
About Scott & White Healthcare (sw.org )
Scott & White Healthcare is a non-profit collaborative health care system established in 1897 in Temple, Texas. Among the leading health systems encompassing one of the nation's largest multi-specialty group practices, Scott & White provides personalized, comprehensive health care enhanced by medical education and research. Scott & White Healthcare includes 13 acute care hospital sites, one emergency hospital site, one additional announced facilities, and over 140 clinics at more than 70 primary care and specialty clinic locations throughout Central Texas providing adult and pediatric care in 46 medical specialties. Integrated, high-quality care is delivered by a dedicated staff of more than 14,000 (including approximately 1,200 physicians and scientists and more than 300 specialized health care providers). Get the latest news from Scott & White Healthcare by visiting our online newsroom, news blog or on Twitter (@swhealthcare).
For more information, contact:
- Deke Jones
Scott & White Healthcare
August 29, 2013